Welcome to our dedicated page for TELEFLEX SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
Teleflex Inc. director Andrew A. Krakauer reported equity awards consisting of common stock and stock options. He received 1,090 shares of Common Stock as a restricted stock unit award that was granted at no cash cost and will vest 100% on the one-year anniversary of the grant date, with an alternative vesting schedule tied to the 2027 annual meeting of stockholders. He also received a Stock Option Award covering 2,397 shares of Common Stock at an exercise price of $129.71 per share, which vests on the same timing basis and expires on May 15, 2036. Following the stock grant, he beneficially owns 8,308.5344 common shares directly, and holds 2,397 stock options from this award.
Teleflex director Gretchen R. Haggerty received new equity awards as board compensation. She acquired 1,090 shares of common stock as a restricted stock unit award and 2,397 stock options to buy common stock at an exercise price of $129.71 per share.
The restricted stock units and options each vest 100% on the one-year anniversary of the May 15, 2026 grant date, with earlier vesting possible at the 2027 annual meeting if she does not stand for re-election and that meeting occurs at least 50 weeks after the 2026 annual meeting. After the stock award, she directly holds 7,395 common shares.
Teleflex Inc. director Candace H. Duncan reported receiving new equity awards. She was granted 1,090 shares of common stock as a Restricted Stock Unit Award under the Teleflex Incorporated 2023 Stock Incentive Plan, and a Stock Option Award for 2,397 shares at an exercise price of $129.71 per share. Both the RSUs and options vest 100% on the one-year anniversary of the May 15, 2026 grant date, or earlier if she does not stand for re-election at the company’s 2027 annual meeting and that meeting occurs at least 50 weeks after the 2026 annual meeting.
Teleflex Inc director Michael J. Tokich received new equity compensation consisting of both restricted stock units and stock options. He was granted 1,090 shares of common stock as a restricted stock unit award and options covering 4,793 shares at an exercise price of $129.71 per share.
Both awards vest 100% on the one-year anniversary of the May 15, 2026 grant date. Vesting can occur earlier if he does not stand for re-election at the company’s 2027 annual meeting, subject to timing conditions tied to the 2026 and 2027 annual stockholder meetings. After these grants, he directly holds 1,090 shares of common stock and 4,793 options.
Teleflex director Neena M. Patil reported equity awards made as part of her compensation. She received 1,090 shares of common stock and 2,397 stock options, both recorded at a grant price of $0.00 per share for reporting purposes.
The options have an exercise price of $129.71 and expire on May 15, 2036. Both the restricted stock unit and option awards vest 100% on the one-year anniversary of the May 15, 2026 grant date, with provisions for earlier vesting tied to the timing of the company’s 2027 annual meeting. Following the stock award, she holds 3,716 common shares directly and 2,397 options.
Teleflex Inc filed an initial insider ownership report for Michael J. Tokich, identifying him as a director of the company. The Form 3 shows no reported purchases, sales, gifts, or other equity transactions, and it lists no derivative positions or holdings at this time.
T. Rowe Price Investment Management filed Amendment No. 6 to a Schedule 13G/A reporting 3,836,207 shares of Teleflex Inc. common stock, equal to 8.7% of the class. The filing lists 3,824,270 shares of sole voting power and 3,836,207 shares of sole dispositive power.
The filing also expressly states that the filer "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner" of the securities. Signature on the amendment is dated 05/15/2026.
Teleflex interim President and CEO Stuart A. Randle reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 289 shares of Common Stock were withheld at $133.06 per share to cover tax liabilities, leaving him with 19,583 shares held directly.
Teleflex grew first-quarter 2026 net revenues to $548.3 million, up 32.3% from a year earlier, driven mainly by the acquired BIOTRONIK Vascular Intervention business and higher volumes of existing products. Despite this growth, gross margin fell to 56.1% from 61.7% due to 2025 tariffs, acquisition-related amortization, quality and inventory costs, and higher logistics expenses.
The company reported a net loss of $8.2 million, compared with net income of $95.0 million a year ago, as selling, general and administrative and research and development expenses rose with the VI Business, restructuring programs and CEO severance. Discontinued operations tied to planned divestitures of the Acute Care, Interventional Urology and OEM businesses also shifted from a $42.7 million profit to a $3.3 million loss, including a $29.0 million valuation allowance. Teleflex expects $2.0 billion in cash proceeds from these sales and plans to use about $1.8 billion of net after-tax proceeds mainly for share repurchases and debt reduction.
Teleflex Incorporated reported mixed first-quarter 2026 results from continuing operations. Revenue reached $548.3 million, up 32.3% year-over-year and 5.1% on a pro forma adjusted constant currency basis, reflecting growth across Vascular Access, Interventional and Surgical categories.
GAAP diluted EPS from continuing operations was a loss of $(0.11), down from earnings of $1.14, driven by higher costs including restructuring, acquisition and amortization charges. Adjusted diluted EPS from continuing operations was $1.39, slightly below $1.44 a year earlier.
The company maintained its 2026 outlook, guiding to GAAP revenue growth of 14.40%–15.40%, pro forma adjusted constant currency revenue growth of 4.50%–5.50%, GAAP EPS of $2.90–$3.20 and adjusted EPS of $6.25–$6.55. Guidance includes about $90 million of stranded costs and excludes benefits from transition and manufacturing services agreements, planned ~$800 million debt reduction and a $1 billion share repurchase program funded largely by pending divestitures. Teleflex expects its Acute Care, Interventional Urology and OEM Strategic Divestitures to close in the second half of 2026 and has appointed Jason Weidman as President and CEO effective June 8, 2026.